PROTEOMICS INTERNATIONAL LABORATORIES LTD — Capital/Financing Update 2021

ASX Release 2 August 2021 ASX code: PIQ

==> picture [222 x 42] intentionally omitted <==

==> picture [222 x 43] intentionally omitted <==

==> picture [222 x 42] intentionally omitted <==

Exercise of Options

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) advises that the Company has today issued 50,000 fully paid ordinary shares ( Shares ) upon the exercise of unquoted corporate advisory options exercisable at $0.50 per option on or before 27 March 2023 raising $25,000 before costs.

An Appendix 2A applying for quotation of the Shares has been lodged separately.

Secondary Trading Notice Pursuant to Paragraph 708A(5)(e) of the Corporations Act 2001 ("Act")

The Act restricts the on-sale of securities issued without disclosure, unless the sale is exempt under section 708 or 708A of the Act. By giving this notice, a sale of the Shares noted above will fall within the exemption in section 708A(5) of the Act.

The Company hereby notifies ASX under paragraph 708A(5)(e) of the Act that:

• (a) the Company issued the Shares without disclosure to investors under Part 6D.2 of the Act;

• (b) as at the date of this Notice, the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company, and section 674 of the Act; and

• (c) as at the date of this Notice, there is no information:

  • i. that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and

  • II. that investors and their professional advisers would reasonably require for the purposes of making an informed assessment of:

    • a. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or

    • b. the rights and liabilities attaching to the relevant Shares.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX.PIQ).

ENDS

For further information please contact:

Dr Richard Lipscombe Managing Director Proteomics International Laboratories Ltd T: +61 8 9389 1992 E: [email protected]

Dirk van Dissel Kyle Moss Corporate Advisor & Investor Relations Corporate Advisor Candour Advisory Euroz Hartleys T: +61 408 326 367 T: +61 8 9488 1400 E: [email protected] E: [email protected]

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia T: +61 8 9389 1992 | E: [email protected] | W: www.proteomicsinternational.com

1 / 1

Part of the PILL Group